Clinical Trial: Evaluate the Safety, Tolerability, and Efficacy of Reduced Nicotinamide Mononucleotide (NMNH) in Healthy Adult Participants

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889740) titled 'Evaluate the Safety, Tolerability, and Efficacy of Reduced Nicotinamide Mononucleotide (NMNH) in Healthy Adult Participants' on March 17.

Brief Summary: This study is to assess the safety and tolerability of IP as a dietary supplement for human consumption. The current study aims to comprehensively evaluate its potential effects on pharmacokinetics, physical performance, biological age and overall quality of life. These findings will expand our understanding of NMNH therapeutic potential and guide its future clinical applications in anti-aging interventions.

Study Start Date: July 08, 2024

Study Type: INTERVENTIONAL

Condition: ...